DrugBank

MAY 15, 2024

In fact, it's one of the most exciting areas in drug research today. With billions in funding and innovative research, we're starting to see strategies that can tackle these tough targets. One approach is to look beyond the traditional drug molecule.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Sygnature Discovery

SEPTEMBER 14, 2023

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

Agency IQ

NOVEMBER 27, 2023

These API-derived nitrosamines are referred to as Nitrosamine Drug Substance Related Impurities (NDSRIs) and represent an unprecedented development with manufacturing, quality, and product safety implications. In a study of more than 12,000 small molecule drugs , researchers found 40.4%

Regulations 40

Regulations Production FDA Marketing 40

Agency IQ

AUGUST 11, 2023

In a study of more than 12,000 small molecule drugs , researchers found 40.4% This means that entire classes of critical drugs (like ACE inhibitors and beta blockers) containing secondary or tertiary amine moieties in their API molecular structures are technically nitrosamine precursors.

FDA 40

FDA Science Production Regulations 40

The Pharma Data

JUNE 11, 2025

By leveraging large-scale genomic datasets and functional assays in human cardiomyocytes, researchers from Bayer and the Broad Institute are working to map the complex gene networks that drive disease progression in DCM and other cardiovascular disorders.

Drug Research 40

Drug Research Research Small Molecule Drugs 40

Drug Target Review

FEBRUARY 11, 2025

Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules. Todays small molecules are far larger, more complex, and chase highly specific (and difficult to hit) targets, thereby increasing the chances of undesired side effects.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59